Učitavanje...
CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors
Background: Homologous recombination deficiency (HRD) is a common molecular characteristic of genomic instability, and has been proven to be a biomarker for target therapy. However, until now, no research has explored the changes in the transcriptomics landscape of HRD tumors. Methods: The HRD score...
Spremljeno u:
| Izdano u: | Theranostics |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Ivyspring International Publisher
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8210593/ https://ncbi.nlm.nih.gov/pubmed/34158843 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.59056 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|